Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Digestive SystemDRG 385-inflammatory-bowel-disease-with-mcc
    Ask Trek AI about this page

    Inflammatory Bowel Disease with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    DRG 385 encompasses inpatient admissions for inflammatory bowel disease accompanied by a Major Complication or Comorbidity, involving higher-acuity clinical presentations such as severe flares, sepsis, or organ dysfunction. It matters for inpatient reimbursement because the Major Complication or Comorbidity status increases expected resource use and typically results in higher Medicare Severity Diagnosis-Related Group payment than lower-severity classifications.

    Customize your policy alerts

    Sign up for drg 385 policy alerts

    Get alerted when payer policies referencing 385 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 385 Overview

    Diagnosis-Related Group 385 covers hospital admissions for inflammatory bowel disease with a Major Complication or Comorbidity and includes patients with severe ulcerative colitis or Crohn disease who experience significant systemic or organ-compromising issues. This Diagnosis-Related Group is relevant for inpatient payment because the presence of a Major Complication or Comorbidity increases resource intensity and influences Medicare Severity Diagnosis-Related Group assignment and reimbursement. Hospitals should document the severity and associated treatments to support accurate coding and payment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute inpatient intervention trials assessing effectiveness and safety of rapid induction therapies for severe inflammatory bowel disease flares: these studies enroll hospitalized adults with ulcerative colitis or Crohn’s disease who present with life‑threatening flares, steroid‑refractory disease, or complications such as severe bleeding, toxic megacolon, or sepsis. They evaluate time‑to‑clinical‑response, need for rescue surgery or ICU transfer, and short‑term adverse events of interventions delivered during the index admission. Results are directly relevant to providers and payers because they inform decisions that shorten length of stay, reduce intensive care utilization, and prevent costly surgical procedures in this high‑acuity DRG.
    • Comparative effectiveness and safety studies of escalation strategies in complicated IBD with major comorbidities: these observational cohorts or randomized pragmatic trials compare therapeutic sequences (for example, biologic versus immunomodulator escalation, combination therapy strategies, or timing of surgical referral) in hospitalized patients who have inflammatory bowel disease plus major complications or comorbid conditions. The patient population includes those with infection, malnutrition, thromboembolic risk, or organ dysfunction that constitute major complication or comorbidity status; outcomes include readmission rates, complication rates, resource use, and functional recovery over 90 days to one year. Findings guide clinicians and payers on which escalation pathways balance effectiveness with safety and overall cost for patients assigned to this DRG.
    • Post‑discharge care coordination and outcomes trials focused on preventing readmission and long‑term disability after an IBD hospitalization with major complications: these pragmatic trials and health services research projects test interventions such as structured discharge planning, early outpatient follow‑up, integrated nutrition and wound/surgical care, and remote monitoring among patients recently discharged after a complicated IBD admission. They study patient populations at high risk for recurrent flares, surgical complications, or poor adherence, measuring 30‑ and 90‑day readmissions, emergency visits, quality of life, and downstream costs. Evidence from this area is critical for payers and hospitals aiming to reduce readmissions, optimize post‑acute resource allocation, and improve long‑term outcomes for patients in DRG 385.

    Related Codes

    326-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITH-MCC

    Stomach, Esophageal and Duodenal Procedures with MCC: Inpatient Reimbursement Overview

    327-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITH-CC

    Stomach, Esophageal and Duodenal Procedures with CC: Inpatient Reimbursement Overview

    328-STOMACH-ESOPHAGEAL-AND-DUODENAL-PROCEDURES-WITHOUT-CC-MCC

    Stomach, Esophageal and Duodenal Procedures without CC/MCC: Inpatient Reimbursement Overview

    329-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITH-MCC

    Major Small and Large Bowel Procedures with MCC: Inpatient Reimbursement Overview

    330-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITH-CC

    Major Small and Large Bowel Procedures with CC: Inpatient Reimbursement Overview

    331-MAJOR-SMALL-AND-LARGE-BOWEL-PROCEDURES-WITHOUT-CC-MCC

    Major Small and Large Bowel Procedures without CC/MCC: Inpatient Reimbursement Overview

    332-RECTAL-RESECTION-WITH-MCC

    Rectal Resection with MCC: Inpatient Reimbursement Overview

    333-RECTAL-RESECTION-WITH-CC

    Rectal Resection with CC: Inpatient Reimbursement Overview

    334-RECTAL-RESECTION-WITHOUT-CC-MCC

    Rectal Resection without CC/MCC: Inpatient Reimbursement Overview

    335-PERITONEAL-ADHESIOLYSIS-WITH-MCC

    Peritoneal Adhesiolysis with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 57

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.